The disposition of cisapride in seven healthy cats was determined following administration of either a single oral (2 mg/kg body weight) or intravenous (i.v.) (1 mg/kg body weight) dose. Cats were studied using a random crossover design. After administration of the oral capsule, maximum plasma drug concentration (Cmax) +/- standard deviation (SD) was 73.32 +/- 16.59 ng/ml, and bioavailability +/- SD was 29.0 +/- 22.6%. Following i.v. administration, extrapolated peak cisapride concentration (C0) +/- SD was 421.30 +/- 155.37 ng/ml, and clearance +/- SD was 15 +/- 0.67 ml/kg per minute. Elimination half-life (T1/2) was similar for both routes of administration (T1/2(oral) +/- SD was 5.27 +/- 3.16 hr, T1/2(i.v.) +/- SD was 5.19 +/- 3.77 hr). Adverse effects were not observed. Based on these results, a dose of 1 mg/kg body weight per os (PO) every eight hours or 1.5 mg/kg body weight every 12 hours is expected to result in plasma drug concentrations within the therapeutic ranges established for humans.
Skip Nav Destination
Article navigation
1 November 1997
Articles|
November 01 1997
Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats
J Am Anim Hosp Assoc (1997) 33 (6): 517–523.
Citation
SN LeGrange, DM Boothe, S Herndon, MD Willard; Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats. J Am Anim Hosp Assoc 1 November 1997; 33 (6): 517–523. doi: https://doi.org/10.5326/15473317-33-6-517
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Long-Term Survival of Primary Intracranial Histiocytic Sarcoma Through Surgical Resection and Low-Dose CCNU
Kyosuke Hidari, DVM, Yuya Nakamoto, DVM, PhD, James K. Chambers, DVM, PhD, Kazuyuki Uchida, DVM, PhD, Isao Mori, DVM, Miwa Nakamoto, DVM
Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma
Nicole Schlette, DVM, Erin Burton, DVM, MS, DACVP, Amber Harris, DVM, DACVIM (Internal Medicine), Kendall Langsten, DVM, DACVP, Erik Olson, DVM, PhD, DACVP, Daniel Heinrich, DVM, DACVP
Chronic Myelomonocytic Leukemia with Central Nervous System Involvement in a Dog
Ilaria Tartari, DVM, Fabio Tocco, DVM, Giorgio Cancedda, DVM, Veronica Angioni, DVM, Marco Podda, DVM, Antonella Gallucci, DVM, PhD, DECVN, EBVS
Treatment Outcomes of Canine Orbital Meningiomas in Seven Cases
Akihiro Uno, DVM, Ryota Iwasaki, DVM, PhD, Takashi Mori, DVM, PhD
Transient Hypoadrenocorticism in a 7-Week-Old Kitten
Alba Planas Vintro, BVM, Linda G. Martin, DVM, MS, DACVECC, Cassidy L. Cordon, DVM, Sabrina N. Hoehne, Dr. med. vet., DACVECC, DECVECC, Elizabeth B. Davidow, DVM, DACVECC